An Oral "Ketamine-Like" NMDA/AMPA Modulation Stack Restores Cognitive Capacity in a Young Man with Schizoaffective Disorder—Case Report

Cognitive impairment, not mood or psychotic symptoms, often causes lasting disability in schizoaffective disorder, but standard medications do not address it. A 22-year-old man with schizoaffective disorder, bipolar type, experienced persistent 'brain fog' that threatened his university graduation despite stable mood and psychosis on lurasidone, olanzapine, and valproate. A combination of Deanxit (flupentixol 0.5 mg + melitracen 10 mg once-daily), dextromethorphan 15 mg twice-daily, and piracetam 600 mg twice-daily led to clearer thinking within two weeks, completion of coursework and passing exams by six weeks, and sustained benefit for three months without mood destabilization or psychotic relapse. The authors suggest this approach targets the NMDA–AMPA axis and warrants controlled trials.

Study at a glance

Abstract

Cognitive impairment—rather than psychosis or mood instability—often drives long-term disability in schizoaffective disorder, yet current antipsychotic and mood-stabilising regimens offer little relief. We describe a 22-year-old man with schizoaffective disorder, bipolar type, whose persistent "brain fog" jeopardised university graduation despite euthymic mood and quiescent psychosis on lurasidone, olanzapine, and valproate. A mechanistically guided add-on protocol was introduced: Deanxit (flupentixol 0.5 mg + melitracen 10 mg once-daily) to provide mild serotonin–noradrenaline enhancement and moderate CYP2D6 inhibition; dextromethorphan 15 mg twice-daily to deliver gentle, σ₁-supported NMDA antagonism; and piracetam 600 mg twice-daily as a positive allosteric modulator of AMPA receptors. Within two weeks the patient reported clearer thinking and sustained reading; family noted coherent conversation and fewer attentional lapses. By six weeks he completed all coursework, passed mid-term examinations, and maintained social engagement—improvements never achieved with previous therapy. Benefits have persisted for three months with no mood destabilisation, psychotic relapse, or significant side-effects apart from transient nausea. We propose that melitracen's CYP2D6 blockade prolonged dextromethorphan exposure, enabling a steady NMDA "priming" signal, while piracetam amplified downstream AMPA throughput to consolidate synaptic plasticity. This case highlights the potential of inexpensive, orally available agents to target the NMDA–AMPA axis and alleviate the cognitive burden of schizoaffective disorder. Controlled trials are warranted.